Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 14/20 | 1.00 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.35 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.35 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1437212 | 0.92 | MDM2 (1.00) | MDM2NOTUMPDE4BPDE4DPGR | |
| SCHEMBL9894042 | 0.90 | MDM2 (0.82) | MDM2NOTUMPDE4BPDE4DKCNJ6 | |
| SCHEMBL9893686 | 0.89 | MDM2 (0.83) | MDM2PDE4BPDE4D | |
| SCHEMBL27862848 | 0.89 | MDM2 (0.80) | MDM2NOTUMPDE4BPDE4D | |
| SCHEMBL27862912 | 0.88 | MDM2 (0.78) | MDM2NOTUMPDE4BPDE4DPGR | |
| SCHEMBL9893743 | 0.87 | MDM2 (0.76) | MDM2 | |
| SCHEMBL9893747 | 0.86 | MDM2 (0.76) | MDM2NOTUMPDE4BPDE4D | |
| SCHEMBL1437674 | 0.85 | MDM2 (0.74) | MDM2PDE4BPDE4DPGR | |
| SCHEMBL9893683 | 0.84 | MDM2 (0.73) | MDM2NOTUMPDE4BPDE4DKCNJ6 | |
| Lithium SCHEMBL9894073 | 0.84 | MDM2 (0.73) | MDM2PDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102574785-A | Tetra-substituted heteroaryl compounds and their use as MDM2 and/or MDM4 modulators | NOVARTIS AG | 2012-07-11 | — | — | CN | disclosed |
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885NOTUM 4675/4885PDE4B 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.